论文部分内容阅读
目的系统评价贝伐单抗在非鳞状非小细胞肺癌治疗中的临床疗效、安全性和地位。方法采用Cochrane系统评价方法进行资料提取、分析、评价。结果共纳入2个研究,929例晚期非鳞状非小细胞肺癌患者。经meta分析表明贝伐单抗/紫杉醇/卡铂方案的疗效优于紫杉醇/卡铂方案,但发生率相对较高。结论贝伐单抗治疗非鳞状非小细胞肺癌有确切临床疗效,与PC方案联合用药比单纯PC方案更适合晚期非鳞状非小细胞肺癌患者。
Objective To evaluate the clinical efficacy, safety and status of bevacizumab in the treatment of non-squamous non-small cell lung cancer. Methods The Cochrane systematic evaluation method was used to extract, analyze and evaluate data. Results A total of 2 studies were included, 929 patients with advanced nonsquamous non-small cell lung cancer. Meta-analysis showed that bevacizumab / paclitaxel / carboplatin regimen was superior to paclitaxel / carboplatin regimen, but the incidence was relatively high. Conclusion Bevacizumab treatment of non-squamous non-small cell lung cancer have a definite clinical effect, combined with the PC program is more suitable than the PC program for advanced non-squamous non-small cell lung cancer patients.